Impaired Myeloid-derived Suppressor Cells Are Associated With Recurrent Implantation Failure: A Case-Control Study

Huanhuan Jiang
First Affiliated Hospital of Anhui Medical University

Mengting Zhu
First Affiliated Hospital of Anhui Medical University

Peipei Guo
First Affiliated Hospital of Anhui Medical University

Kaihuan Bi
First Affiliated Hospital of Anhui Medical University

Zhimin Lu
First Affiliated Hospital of Anhui Medical University

Caihua Li
First Affiliated Hospital of Anhui Medical University

Muxin Zhai
First Affiliated Hospital of Anhui Medical University

Kangxia Wang
First Affiliated Hospital of Anhui Medical University

Yunxia Cao (✉ caoyunxia6@126.com)
First Affiliated Hospital of Anhui Medical University

Research

**Keywords:** recurrent implantation failure, myeloid-derived suppressor cells, maternal-fetal immune tolerance, regulatory T cells

**DOI:** https://doi.org/10.21203/rs.3.rs-86597/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.

Read Full License
Abstract

Background: Studies have reported that myeloid-derived suppressor cells (MDSCs) contribute to maintain pregnancy. The aim of this case-control study was to test whether there is a dysregulation of peripheral MDSCs in recurrent implantation failure (RIF).

Methods: 26 RIF patients and 30 controls were recruited. Flow cytometry was applied to characterize polymorphonuclear (PMN)-MDSCs, monocytic-MDSCs (M-MDSCs), effector T cells (Teffs) and regulatory T cells (Tregs) in blood. ELISA was used to define MDSCs correlative cytokines and chemokines in serum from all patients.

Results: Compared with controls, RIF patients showed significant reductions of blood PMN-MDSCs, M-MDSCs, Tregs and NO production by PMN-MDSCs, whereas the expression of ζ chain on CD4^+ T cell receptor (TCR) and CD8^+ TCR displayed a remarkable upregulation in RIF patients. Moreover, RIF patients presented a lower concentration of serum chemokine (C-C motif) ligand (CCL) 5 and transforming growth factor (TGF)-β than those from controls. Furthermore, the level of TCR ζ chain on CD4^+ and CD8^+ Teffs was negatively correlated not only with the percentage of PMN-MDSCs, but also with the amount of NO produced by PMN-MDSCs. The frequency of PMN-MDSCs had positive correlations with the concentration of CCL5 and TGF-β.

Conclusions: This study indicated that the dysregulation of MDSCs might impair maternal-fetal immune balance thus resulting in RIF.

Introduction

Recurrent implantation failure (RIF) is diagnosed when women experienced 3 or more frozen or fresh cycles with being transferred high-quality embryos and failed to obtain a clinical pregnancy [1, 2]. Numerous studies have found that the identifiable causes include parental chromosomal abnormalities, defective embryonic development, uterine anatomic anomalies, and poor endometrium [3–6]. Nevertheless, more and more researches have focused on the immunological aspects, especially a failure to establish maternal-fetal immunotolerance for successful implantation.

Lédée et al. reports that, at the time of embryo implantation, the maternal immune system is featured by distinct immunological alterations with enrichment of various immune cells in both peripheral circulation and uterus microenvironment [7]. These changes make an immunological tolerance environment which protects embryo expressing paternal antigen from maternal antigen-specific T cells and contributes to successful implantation [7]. Breakdown of maternal-fetal tolerance was found to be associated with a poor clinical outcome in pregnant women [8, 9]. Furthermore, dysregulation of implicated immune cells such as uterine natural killer cells (NK), peripheral NK, regulatory T cells (Tregs), T-helper cells have been discovered in RIF [10–13].
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous cell group with attributes in myeloid origin, immature state, and immunosuppressive function [14]. Under pathogenic condition, MDSCs are accumulated by an inflammatory condition which contains mediators such as transforming growth factor (TGF)-β, tumor necrosis factor (TNF)-α, interleukin (IL)1β, IL-6, IL-10 and chemokines such as chemokine (C-C motif) ligand (CCL) 2, CCL3, CCL4, CCL5 [15, 16]. They exert immunosuppressive function by different mechanisms: the activation of arginase-1 (Arg-1) and inducible nitric oxide synthase (iNOS) which generates nitric oxide (NO) [14]. These pathways caused a dysregulation of T cell functions by downregulating the ζ chain expression on T cell receptor (TCR), which has a key role in the TCR-mediated antigen recognition and signal transduction [14, 17]. In mice, MDSCs can be divided into CD11b+Ly6G−Ly6C<sub>high</sub> monocytic MDSCs (M-MDSCs) and CD11b+Ly6G+Ly6C<sub>low</sub> polymorphonuclear MDSCs (PMN-MDSCs). In human, they are identified as CD33+HLA-DR<sub>−/low</sub>CD11b+CD14+CD15<sup>−</sup> M-MDSCs and CD33+HLA-DR<sup>−/low</sup>CD11b<sup>+</sup>CD14<sup>−/low</sup>CD15<sup>+</sup> PMN-MDSCs [18]. MDSCs have been reported to expand in different pathological conditions such as cancer, traumas and infectious diseases [19–21]. Because of the immunosuppressive effect of MDSCs, studies focused on their roles in pregnancy and associated complications in recent years [22–26]. Studies demonstrated that MDSCs expanded not only in uterus but also in peripheral blood during gestation period [22, 24]. In human, PMN-MDSCs are accumulated in peripheral circulation of healthy pregnant women as compared to nonpregnant controls [27, 28]. Reduction of MDSCs was explored both in decidua and in peripheral blood from miscarriage patients [29]. In addition, depletion of MDSCs was found to result in a significant decrease of Tregs and severe embryo resorption in mice model [30].

These growing evidences strengthen that MDSCs have a strong ability to promote maternal immune tolerance. However, whether peripheral MDSCs are associated with RIF is still unknown. In this study, we have assessed the level and function of MDSCs along with its subtypes in RIF patients and pregnant women with first IVF. Our study is the initial research that discovers the reduction of PMN-MDSCs in RIF patients. These findings provide a strategy with which inducing MDSCs could be utilized as a therapeutic option in RIF women.

**Materials And Methods**

**Patient selection**

In our study, 26 RIF patients and 30 controls were recruited from the Reproductive Medicine Center of the First Affiliated Hospital of Anhui Medical University. All RIF patients were transferred high-quality embryos in more than 3 fresh or frozen cycles and failed to achieve clinical pregnancy. Ultrasonography and hysteroscopy were applied to confirm that every RIF patient had a normal morphology and thickness of endometrium and a normal uterine cavity. Women who underwent the first IVF-embryo transfer (ET) cycles because of oviduct infertility were recruited, and the ones who obtained clinical pregnancy were identified as control group. All patients whose ages ranged from 22 to 38 in this study had a normal ovarian reserve and accepted frozen ET. The exclusive criteria for all the volunteers were as follows: hydrosalpinx, genetic or anatomic abnormalities, polycystic ovary syndrome, endometriosis,
adenomyosis, recurrent spontaneous abortion, autoimmune disorder, infectious diseases, immunomodulator treatment which might affect immune system 1 year prior to the study. Characteristics of patients are listed in Table 1. The Ethics Review Board of the First Affiliated Hospital of Anhui Medical University has approved the study (PJ2018-07-20). All patients signed informed consent.

**Sample collection**

Blood samples were taken 1-2 hours before embryo transfer. Peripheral blood mononuclear cells (PBMCs) were obtained from heparinized venous blood by density gradient centrifugation using Ficoll-Paque 1.077 g/ml (GE Healthcare, Sweden). The serum was stored at -80°C and the cell pellets were adjusted to 10^7 cells and cryopreserved at -80°C. The cryopreservation medium was Roswell Park Memorial Institute supplemented with 30% human serum and 10% Dimethyl Sulphoxide.

**Flow cytometry analysis of human PBMCs**

The following anti-human antibodies (mAbs) used are listed in Table 2. PBMCs (1 ×10^6/mL) were preincubated with human True-Stain Monocyte Blocker™ (Biolegend, USA) to block nonspecific binding and cells were stained with different combinations of antibodies listed in Table 2. 4,5-Diaminofluorescein Diacetate (DAF-2DA; Abcam, USA) was stained for NO production according to the manufacturer's recommendation. During the intracellular staining of Foxp3, cells were preincubated with the Foxp3 fixation/permeabilization kit (eBioscience, USA) following the instruction. Acquisition was performed by FACSVerse™ with FACSuite software. The compensation control was performed. Data with at least 100,000 events was analyzed with FlowJo software (Tree Star). Pseudocolor were used in the study.

**ELISA assay in human serum**

The serum was thawed, and 11 cytokines were analyzed by ELISA kit (Multisciences Biotech, China) according to the instruction manual. They were: TGF-β, IL-1β, IL-6, IL-10, Interferon-g, granulocyte macrophage colony-stimulating factor, TNF-a, CCL2, CCL3, CCL4 and CCL5.

**Statistical analysis**

GraphPad Prism software was applied for statistical analysis. For two groups, an unpaired two-tailed Student's t test was implemented. Results were tested with a Chi-squared analysis test for categorical variables. Correlations between MDSCs and other factors were detected by Spearman analysis. Correlation coefficient is showed as r. P < 0.05 was considered a statistically significant difference.

**Results**

**Impairment of MDSCs in RIF patients**

We examined MDSCs in the PBMCs from patients of each group. Using flow cytometry, we characterized M-MDSCs as CD33^+HLA-DR^-/lowCD11b^+CD14^+CD15^- cells and PMN-MDSCs as CD33^+HLA-
DR-/lowCD11b+CD14-CD15+ cells (Fig. 1a). The frequencies of these two subpopulations were measured as a percentage within live cells. RIF patients showed a decreased frequency of PMN-MDSCs (Fig. 1b, $P < 0.001$) and M-MDSCs (Fig. 1c, $P < 0.01$) as compared with those in control group. Meanwhile, we investigated suppressive potential of MDSCs by assessing NO production in these cells. Intracellular NO production was detected by DAF-2DA utilizing mean fluorescence intensity (MFI). NO production by PMN-MDSCs of RIF women was significantly decreased as compared to controls (Fig. 1d, $P < 0.01$). Whereas the level of intracellular NO of M-MDSCs was similar between both groups.

**Immunosuppressive effect of MDSCs in RIF patients**

Subsequently, we examined the effect of MDSCs on effector T cells (Teffs) in each group. Teffs were identified as CD3+CD4+Foxp3- and CD3+CD8+Foxp3- (Fig. 2a). We found that the frequency of CD4+ and CD8+Teffs in two groups remained mostly at the same level, however, RIF patients showed an upregulation of TCR ζ chain expression on CD4+ (Fig. 2b, $P < 0.05$) and CD8+Teffs (Fig. 2c, $P < 0.05$) as compared to those in controls.

**Reduction of Tregs in patients with RIF**

Next, we identified Tregs as CD3+CD4+CD25+CD127lowFoxp3+ cells (Fig. 3a), and the frequency of Tregs has been calculated among live cells. We discovered a decreased level of Tregs in RIF patients as compared to this value in control group (Fig. 3b, $P < 0.01$).

**Cytokines in RIF women**

We investigated the serum chemokines or cytokines in two groups and demonstrated that the concentrations of CCL5 and TGF-β in RIF women were significantly lower than those in controls (Fig. 4a, $P < 0.05$ and Fig. 4b, $P < 0.01$). No statistically significant differences in levels of other investigated cytokines and chemokines were found.

**The correlation between MDSCs and other factors**

There was a significant negative correlation between the percentage of PMN-MDSCs and the expressions of CD4+TCR ζ chain (Fig. 5a, $r = -0.412, P < 0.01$) and CD8+TCR ζ chain (Fig. 5b, $r = -0.3509, P < 0.01$). Moreover, the production of NO produced by PMN-MDSCs displayed negative correlations with the levels of CD4+TCR ζ chain (Fig. 5c, $r = -0.3706, P < 0.01$) and CD8+TCR ζ chain (Fig. 5d, $r = -0.4539, P < 0.001$). Whereas, there was a positive relationship between the level of PMN-MDSCs and the level of CCL5 (Fig. 5e, $r = 0.4317, P < 0.01$) and TGF-β (Fig. 5f, $r = 0.4383, P < 0.01$). We did not find any correlation between the level of PMN-MDSCs and other cells, nor was there any relevance between the percentage of M-MDSCs and other cells and cytokines.

**Discussion**
Embryo implantation is an exceedingly complex, convoluted process of reproductive biology. An immunity homeostasis induced by maternal fetal cross-talk protects semi-allogeneic fetus from attacking by powerful maternal immune system. Pregnancy-induced immunomodulatory effects present in local of maternal-fetal interface as well as circulation of maternal system.

In the last decades, the contribution of MDSCs to maternal-fetal immunotolerance has been recognized [22, 23]. Their roles have been described in different situations, early and mid-term pregnancy, early miscarriage, the neonatal period and preeclampsia [24, 27, 29, 31]. Little is known, however, about the effects of MDSCs on the window of implantation (WOI) in RIF patients. To clarify this question, we investigated the patterns of MDSCs in peripheral blood from RIF women on the day of ET to determine whether MDSCs are involved in immunotolerance during WOI.

In present study, we found impressive impairments in frequency of peripheral blood MDSCs from women with RIF as compared to those from control group. These data are comparable to previous studies which described that the ratio of MDSCs among PBMCs showed a positive correlation with pregnancy rate in IVF patients [26]. MDSCs have been demonstrated to be one of the powerful immunosuppressive cells and tied up with maternal immune tolerance [32]. Köstlin and his group observed that healthy pregnant women have a significant accumulation of PMN-MDSCs in the blood during all stages of pregnancy [27]. Studies in human and mice report that a decreased percentage and activity of MDSCs in peripheral blood is associated with early miscarriage [9, 29, 33, 34]. In microenvironment, MDSCs secret iNOS to catabolize L-Arg to citrullin and produce NO which downregulates the expression of the TCR \(\zeta\) chain on T cells hence restrain T cells activity [14]. As a pivotal antigen-recognition cells population in human, activated T cells may be a threat to the embryo expressing paternal antigen [35]. In agreement with these observations, when we considered measurement of intracellular NO as a biomarker of immunosuppressive potential for MDSCs [14] and compared those in each group, we found a significant reduction in intracellular NO produced by PMN-MDSCs from RIF patients. On the contrary, the levels of TCR \(\zeta\) chain on CD4\(^+\) and CD8\(^+\)Teffs are significantly upregulated in RIF patients. Moreover, the level of TCR \(\zeta\) chain on CD4\(^+\) and CD8\(^+\)Teffs was negatively correlated not only with the percentage of PMN-MDSCs, but also with the amount of NO produced by PMN-MDSCs.

MDSCs have been demonstrated to maintain maternal-fetal tolerance by inducing Foxp3 expression in CD4\(^+\)CD25\(^-\)T cells, hence expanding Tregs [30]. Tregs as a subpopulation of suppressor cells, express the transcription factor Foxp3 and play a critical role in preventing semi-allogeneic fetus from maternal immune system [36]. Anergia of conceptus-specific T cells during pregnancy relies on the persistent presence of Tregs [35]. Enhancement of Tregs in peripheral blood is concerned with a better IVF treatment outcome [37], whereas reduction of peripheral Tregs is associated with reproductive failure [38]. In line with these observations, we found an exhaustion of Tregs in RIF patients. However, the proportion of Tregs were not relevant to the proportion of MDSCs in this study. This may be due to the fact that Tregs can also be induced by hormones [39].
MDSCs require different signal molecules for their migration, proliferation and activation to suppress the immune response [15, 16]. CCL5 was reported to play a vital role in the recruitment and activation of MDSCs as well as the generation and mobilization of MDSCs [15]. Similar to these studies, we found a decrease of serum CCL5 in RIF patients as compared to controls. Moreover, our data showed that the level of serum CCL5 was positively correlated with PMN-DSCs. Using animal model, Bae et al. described that CCL5 may be involved in or promote the placentonal development [40]. Taken together, we would suggest that impaired CCL5 and MDSCs could be a cause for RIF. Furthermore, our finding revealed that RIF patients displayed a significantly lower concentration of serum TGF-β as compared to control women. As a major effective media, TGF-β was reported to be secreted by MDSCs and activate several signaling pathways in MDSCs, and consequently augment immunosuppressive capacity of MDSCs [14]. Meanwhile, as an important anti-inflammatory cytokine, TGF-β was significantly decreased in plasma from RIF patients [41]. Our study found that the concentration of serum TGF-β presents a positive correlation with the percentage of PMN-MDSCs. These discoveries provide further evidence that an appropriate amount of MDSCs may contribute to embryo implantation, whereas depletion of MDSCs is detrimental to embryo implantation.

Conclusion

Our study discovers the differential expression of MDSCs and their related mediators in RIF and control group. These outcomes revealed that the dysregulation of MDSCs might impair maternal-fetal immune balance thus resulting in RIF. Therefore, targeting these cells might provide new treatment methods in the future.

Abbreviations

RIF, Recurrent implantation failure; IVF, in vitro fertilization; ET, embryo transfer; NK, natural killer cells; Tregs, regulatory T cells; MDSCs, myeloid-derived suppressor cells; PMN-MDSCS, polymorphonuclear myeloid-derived suppressor cells; M-MDSCs, monocytic myeloid-derived suppressor cells; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; IL, interleukin; CCL, chemokine (C-C motif) ligand ; Arg-1, arginase-1; iNOS, inducible nitric oxide synthase; NO, nitric oxide; TCR, T cell receptor; PBMCs, peripheral blood mononuclear cells; Teffs, effector T cells; MFI, mean fluorescence intensity; WOI, window of implantation

Declarations

Acknowledgements

The authors acknowledge staff from the Obstetrics and Gynecology Department and the Anhui Provincial Key Laboratory of Reproductive Health and Genetics. We also thank English teacher Nicky Werner for language help.
Authors contributions

Author contributions: KW and YC participated in study design and manuscript drafting. HJ, MZ and PG contributed to study conduct and data analysis. KB and ZL helped to prepare samples. CL helped with the acquisition of clinical data. All authors approved the final version of this manuscript and are responsible for the aspects of the work.

Funding

This work was supported by the National Natural Science Foundation of China for Young Scholars (grant number 81701421) and the Anhui Provincial Natural Science Fund (grant number 1808085QH273).

Availability of data and materials

The data supporting the conclusions of this article are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the Ethics Review Board of the First Affiliated Hospital of Anhui Medical University, China (No. PJ2018-07-20). Written informed consent was signed by all patients.

Consent for publication

Not applicable.

Competing interests

The authors report no competing interests.

References

1. Macklon N. Recurrent implantation failure is a pathology with a specific transcriptomic signature. Fertil Steril. 2017;108:9-14.
2. Sato T, Sugiura-Ogasawara M, Ozawa F, Yamamoto T, Kato T, Kurahashi H, et al. Preimplantation genetic testing for aneuploidy: a comparison of live birth rates in patients with recurrent pregnancy loss due to embryonic aneuploidy or recurrent implantation failure. Hum Reprod. 2019;34:2340-8.
3. Yuan X, Saravelos SH, Wang Q, Xu Y, Li TC, Zhou C. Endometrial thickness as a predictor of pregnancy outcomes in 10787 fresh IVF-ICSI cycles. Reprod Biomed Online. 2016;33:197-205.
4. Corroenne R, Legendre G, May-Panloup P, Hachem HEI, Dreux C, Jeanneteau P, et al. Surgical treatment of septate uterus in cases of primary infertility and before assisted reproductive technologies. J Gynecol Obstet Hum Reprod. 2018;47:413-8.
5. Park HS, Kim JO, An HJ, Ryu CS, Ko EJ, Kim YR, et al. Genetic polymorphisms of the cobalamin transport system are associated with idiopathic recurrent implantation failure. J Assist Reprod Genet. 2019;36:1513-22.

6. Quintero-Ronderos P, Jiménez KM, Esteban-Pérez C, Ojeda DA, Bello S, Fonseca DJ, et al. FOXD1 mutations are related to repeated implantation failure, intra-uterine growth restriction and preeclampsia. Mol Med. 2019;25:37.

7. Lédée N, Petitbarat M, Chevrier L, Vitoux D, Vezmar K, Rahmati M, et al. The uterine immune profile may help women with repeated unexplained embryo implantation failure after in vitro fertilization. Am J Reprod Immunol. 2016;75:388-401.

8. Ehrentraut S, Sauss K, Neumeister R, Luley L, Oettel A, Fettke F, et al. Human miscarriage is associated with dysregulations in peripheral blood-derived dendritic cell subsets. Front Immunol. 2019;10:2440.

9. Verma P, Verma R, Nair RR, Budhwar S, Khanna A, Agrawal NR, et al. Author information. Altered crosstalk of estradiol and progesterone with myeloid-derived suppressor cells and Th1/Th2 cytokines in early miscarriage is associated with early breakdown of maternal-fetal tolerance. Am J Reprod Immunol. 2019;81: e13081.

10. Seshadri S, Sunkara SK. Natural killer cells in female infertility and recurrent miscarriage: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:429-38.

11. Jiang R, Yan G, Xing J, Wang Z, Liu Y, Wu H, et al. Abnormal ratio of CD57+ cells to CD56+ cells in women with recurrent implantation failure. Am J Reprod Immunol. 2017;78: e12708.

12. Royster GD, Harris JC, Nelson A, Castro Y, Weitzel R., Tisdale J, et al. Rapamycin corrects T regulatory cell depletion and improves embryo implantation and live birth rates in a murine model. Reprod Sci. 2019;26:1545-56.

13. Sheikhansari G, Soltani-Zangbar MS, Pourmoghadam Z, Kamrani A, Azizi R, Aghебati-Maleki L, et al. Oxidative stress, inflammatory settings, and microRNA regulation in the recurrent implantation failure patients with metabolic syndrome. Am J Reprod Immunol. 2019;82:e13170.

14. Vetsika EK, Koukos A, Kotsakis A. Myeloid-derived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer. 2019;8: 1647.

15. Hawila E, Razon H, Wildbaum G, Blattner C, Sapir Y, Shaked Y, et al. CCR5 directs the mobilization of CD11b+ Gr1+ Ly6Clow polymorphonuclear myeloid cells from the bone marrow to the blood to support tumor development. Cell Rep. 2017;21:2212–22.

16. Li BH, Garstka MA, Li ZF. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol Immunol. 2019;117:201-15.

17. Hassel JC, Jiang H, Bender C, Winkler J, Sevko A, Shevchenko I, et al. Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). 2017;6:e1326440.

18. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
19. Wu SY, Chiang, CS. Distinct Role of CD11b+Ly6G-Ly6C- Myeloid-derived cells on the progression of the primary tumor and therapy-associated recurrent brain tumor. Cells. 2019;9:51.

20. Kustermann M, Klingspor M, Huber-Lang M, Debatin KM, Strauss G. Immunostimulatory functions of adoptively transferred MDSCs in experimental blunt chest trauma. Sci Rep. 2019;9:7992.

21. Hollen MK, Stortz JA, Darden D, Dirain ML, Nacionales DC, Hawkins RB, et al. Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis. Crit Care. 2019;23:355.

22. Pan T, Liu Y, Zhong LM, Shi MH, Duan XB, Wu K, et al. Myeloid-derived suppressor cells are essential for maintaining feto-maternal immunotolerance via STAT3 signaling in mice. J Leukoc Biol. 2016;100:499–511.

23. Zhao H, Kalish F, Schulz S, Yang Y, Wong RJ, Stevenson DK. Unique roles of infiltrating myeloid cells in the murine uterus during early to midpregnancy. J Immunol. 2015;194:3713-22.

24. Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D, Carter D, Clements VK. Frontline science: myeloid-derived suppressor cells (MDSC) facilitate maternal-fetal tolerance in mice. J Leukoc Biol. 2017;101:1091–101.

25. Köstlin-Gille N, Dietz S, Schwarz J, Spring B, Pauluschke-Frhlich J, Poets CF, Gille C. HIF-1α-deficiency in myeloid cells leads to a disturbed accumulation of myeloid derived suppressor cells (MDSC) during pregnancy and to an increased abortion rate in mice. Front Immunol. 2019;10:161.

26. Hu C, Zhen Y, Pang B, Lin X, Yi H. Myeloid-derived suppressor cells are regulated by estradiol and are a predictive marker for IVF outcome. Front Endocrinol. (Lausanne) 2019;10:521.

27. Köstlin N, Kugel H, Spring B, Leiber A, Marmé A, Henes M, et al. Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses. Eur J Immunol. 2014;44:2582-91.

28. Bartmann C, Junker M, Segerer SE, Hausler SF, Krockenberger M, Kammerer U. CD33(+) / HLA-DR (neg) and CD33(+) /HLA-DR (+/-) Cells: rare populations in the human decidua with characteristics of MDSC. Am J Reprod Immunol. 2016;75:539–56.

29. Nair RR, Sinha P, Khanna A, Singh K. Reduced myeloid-derived suppressor cells in the blood and endometrium is associated with early miscarriage. Am J Reprod Immunol. 2015;73:479-86.

30. Kang X, Zhang X, Liu Z, Xu H, Wang T, He L, Zhao A. Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25 T cells by activation of the TGF-beta/beta-catenin pathway. Mol Hum Reprod. 2016;22:499–511.

31. Schwarz J, Scheckenbach V, Kugel H, Spring B, Pagel J, Härtel C. Granulocytic myeloid-derived suppressor cells (GR-MDSC) accumulate in cord blood of preterm infants and remain elevated during the neonatal period. Clin Exp Immunol. 2018;191:328–37.

32. Gantt S, Gervassi A, Jaspan H, Horton H. The role of myeloid-derived suppressor cells in immune ontogeny. Front Immunol. 2014;5:387.
33. Ren J, Zeng W, Tian F, Zhang S, Wu F, Qin X, et al. Myeloid-derived suppressor cells depletion may cause pregnancy loss via upregulating the cytotoxicity of decidual natural killer cells. Am J Reprod Immunol. 2019;81:e13099.

34. Ren J, Zeng W, Tian F, Wu F, Zhang S, Liu X, Lin Y. Differential gene expression profile in monocytic myeloid-derived suppressor cells at maternal-fetal interface in a mouse model of spontaneous abortion. J Cell Physiol. 2019;234:10789-99.

35. Erlebacher A. Mechanisms of T cell tolerance towards the allogeneic fetus. Nat Rev Immunol.2013;13:23-33.

36. Robertson SA, Care AS, Moldenhauer LM. Regulatory T cells in embryo implantation and the immune response to pregnancy. J Clin Invest. 2018;128: 4224-35.

37. Zhou J, Wang Z, Zhao X, Wang J, Sun H, Hu Y. An increase of Treg cells in the peripheral blood is associated with a better in vitro fertilization treatment outcome. Am J Reprod Immunol. 2012;68:100–6.

38. Lu Y, Zhang F, Zhang Y, Zeng B, Hu L, Liao A. Quantitative reduction of peripheral CD4⁺ CD25⁺ FOXP3⁺ regulatory T cells in reproductive failure after artificial insemination by donor sperm. Am J Reprod Immunol. 2013;69: 188-93.

39. Thiele K, Hierweger AM, Riquelme JIA, Solano ME, Lydon JP, Arck PC. Impaired Progesterone-Responsiveness of CD11c⁺ Dendritic Cells Affects the Generation of CD4⁺ Regulatory T Cells and Is Associated with Intrauterine Growth Restriction in Mice. Front Endocrinol (Lausanne). 2019;10:96.

40. Bae H, Lee JY, Song G, Lim W. Function of CCL5 in maternal-fetal interface of pig during early pregnancy. Dev Comp Immunol. 2020;103:103503.

41. Liang PY, Diao LH, Huang CY, Lian RC, Chen X, Li GG. The pro-inflammatory and anti-inflammatory cytokine profile in peripheral blood of women with recurrent implantation failure. Reprod Biomed Online.2015;31:823-6.

Tables
Table 1
Basic information of RIF patients and control group.

|                                | RIF patients | CG     | P-value  |
|--------------------------------|--------------|--------|----------|
|                                | n = 26       | n = 30 |          |
| Female age (years) a           | 30.58 ± 4.13 | 29.57 ± 3.57 | 0.330    |
| Male age (years) a             | 30.58 ± 5.08 | 31.00 ± 3.90 | 0.726    |
| BMI (kg/m<sup>2</sup>) a       | 22.29 ± 2.87 | 22.35 ± 3.82 | 0.936    |
| Baseline FSH (IU/L) a          | 6.38 ± 0.48 | 7.03 ± 2.06 | 0.479    |
| Baseline LH (IU/L) a           | 4.68 ± 2.12 | 4.29 ± 1.91 | 0.7019   |
| Primary infertility b          | 18/26(69.23%) | 12/30(40%) | 0.029*   |
| Secondary infertility b        | 8/26(30.77%) | 18/30(60%) |          |
| No. of Retrieved oocytes a     | 15.08 ± 1.25 | 15.03 ± 1.35 | 0.9814   |
| No. of MII a                   | 14.31 ± 1.14 | 13.6 ± 1.20 | 0.6735   |
| No. of fertilized eggs a       | 13.27 ± 1.11 | 12.6 ± 1.12 | 0.6748   |
| No. of cleavage a              | 13.19 ± 1.11 | 12.37 ± 1.10 | 0.5964   |
| No. of 2PN a                   | 10.77 ± 1.06 | 9.77 ± 1.00 | 0.4937   |
| No. of obtained embryo a       | 7.23 ± 0.71 | 6.73 ± 0.75 | 0.5068   |
| No. of high quality embryo a   | 6.28 ± 0.76 | 6.10 ± 0.76 | 0.8534   |
| No. of endometrium thickness a | 10.34 ± 0.35 | 11.36 ± 0.32 | 0.9627   |

Data are presented as means ± standard deviation (SD) or n%. <sup>a</sup> unpaired Student’s t-test, <sup>b</sup> Chi-square test.

RIF-recurrent implantation failure; CG-control group; BMI-body mass index; FSH-follicle stimulating hormone; LH-luteinizing hormone.

*P< 0.05
Table 2
Antibodies used for MDSCs, Tregs, Teffs.

| Antibodies                                      | Company                 |
|------------------------------------------------|-------------------------|
| CD33 Monoclonal Antibody, PE-Cy7               | Biolegend, USA          |
| CD11b Monoclonal Antibody, APC                 | BD Biosciences, USA     |
| HLA-DR Monoclonal Antibody, APC-H7             | Biolegend, USA          |
| CD14 Monoclonal Antibody, Perp-Cy5.5           | BD Biosciences, USA     |
| CD15 Monoclonal Antibody, PE                   | BD Biosciences, USA     |
| CD3 Monoclonal Antibody, FITC                  | BD Biosciences, USA     |
| CD4 Monoclonal Antibody, PE-Cy7                | BD Biosciences, USA     |
| CD25 Monoclonal Antibody, PE                   | BD Biosciences, USA     |
| C127 Monoclonal Antibody, Perp-Cy5.5           | BD Biosciences, USA     |
| Foxp3 Monoclonal Antibody, APC                 | BD Biosciences, USA     |
| CD3 Monoclonal Antibody, AF647                 | BD Biosciences, USA     |
| CD4 Monoclonal Antibody, Perp-Cy5.5            | BD Biosciences, USA     |
| CD8 Monoclonal Antibody, APC                   | BD Biosciences, USA     |
| CD247 Monoclonal Antibody, FITC                | BD Biosciences, USA     |
| Foxp3 Monoclonal Antibody, PE                  | BD Biosciences, USA     |